C
CASI Pharmaceuticals, Inc.
Profile managed by Bizz IdCASI Pharmaceuticals
Estados Unidos
11-50 employees
1991
Description
NASDAQ-listed (CASI) biopharmaceutical founded in 1991, headquartered in Rockville, MD with subsidiary in Beijing. Develops and commercializes treatments for myeloma, leukemia and lymphoma. Key product: EVOMELA (melphalan IV). Pipeline: CD19 CAR-T, anti-Fc?RIIB, VCP/p97 inhibitor and anti-CD38.